Details for New Drug Application (NDA): 211013
✉ Email this page to a colleague
The generic ingredient in NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) is nitrofurantoin; nitrofurantoin, macrocrystalline. There are twenty drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the nitrofurantoin; nitrofurantoin, macrocrystalline profile page.
Summary for 211013
Tradename: | NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) |
Applicant: | Inventia |
Ingredient: | nitrofurantoin; nitrofurantoin, macrocrystalline |
Patents: | 0 |
Suppliers and Packaging for NDA: 211013
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) | nitrofurantoin; nitrofurantoin, macrocrystalline | CAPSULE;ORAL | 211013 | ANDA | NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8531 | 0615-8531-10 | 10 CAPSULE in 1 BLISTER PACK (0615-8531-10) |
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) | nitrofurantoin; nitrofurantoin, macrocrystalline | CAPSULE;ORAL | 211013 | ANDA | NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8531 | 0615-8531-14 | 14 CAPSULE in 1 BLISTER PACK (0615-8531-14) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 75MG;25MG | ||||
Approval Date: | Feb 18, 2022 | TE: | AB | RLD: | No |
Complete Access Available with Subscription